Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

0(0%)

Results Posted

50%(2 trials)

Phase Distribution

Ph phase_3

40%

Ph phase_1

40%

Ph phase_2

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

2(40.0%)

Phase 2Efficacy & side effects

1(20.0%)

Phase 3Large-scale testing

2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Other(1)

Detailed Status

Completed4

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 12 (40.0%)

Phase 21 (20.0%)

Phase 32 (40.0%)

Trials by Status

unknown120%

completed480%

Recent Activity

0 active trials

Showing 5 of 5

completedphase_1

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

NCT00083551

unknownphase_3

Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon

NCT00226408

Clinical Trials (5)

Showing 5 of 5 trials

NCT04988217Phase 1

Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19)

Completed

NCT03066947Phase 1

SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer

Completed

NCT04349410Phase 2

The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol

Completed

NCT00083551Phase 3

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

Completed

NCT00226408Phase 3

Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon

Unknown

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5